it’s early days regarding shorts. The share price is probably at...

it’s early days regarding shorts. The share price is probably at its most vulnerable in terms of shareholder value lost when the share price starts to move up but there is no foundation supporting a higher share price e.g. an approved indication. I guess the shorts weigh up the potential of possible gains against time taken and progress in clinical development. At the moment they don’t want to short heavily because they could get burned on good news such as partnerships for ROW trofinitide or similar which could arrive sooner than later. Perhaps after partnership deals are done and trofinitide is approved we would see the share price move up significantly but then fall prey to heavy shorting over an extended period while NNZ22591 works its way through the trials. In any case I think the rationale for shorting en masse isn’t there yet.